Page 6 - Presection News Today

Extended follow-up from the CheckMate 274 trial further supports adjuvant nivolumab as a standard of care for patients with resected muscle-invasive urothelial carcinoma.

Two new studies report results with adjuvant chemotherapy in older patients with stage 3 colorectal cancer; those who can tolerate it have better outcomes.

A US trial showing that sublobar resection achieves similar survival outcomes as lobar resection could usher in precision lung cancer surgery, says expert.

Cell-free DNA concentration is significantly increased in the first 2 weeks after surgery but these higher levels do not seem to interfere with monitoring of circulating tumor DNA for prognostic purposes.

The agency expanded the indication for pembrolizumab to the adjuvant setting for patients with stage IB-IIIA NSCLC following surgery and platinum-based chemo.

Patients with diffuse low-grade glioma should undergo early, extensive resection, urge researchers reporting survival benefits from this intervention.

Despite an increase in the incidence of advanced and metastatic rectal cancer, overall survival has improved, probably because of improvements in treatment, a new analysis concludes.

Half of patients with unresectable, locally recurrent CRC were alive at 5 years, a notable improvement over standard treatment. The study was published as a preprint and has not been peer reviewed.

The new research brings data to an area of ambiguity, but the findings come with caveats.

Patients with stage IIA and IIB esophageal squamous cell carcinoma with lymphovascular invasion but negative lymph nodes do not benefit. The study was published as a preprint and has not yet been peer reviewed.